Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 730 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR News digest – targeted radiation beam, precision medicine and our early... October 17, 2020 The Mediterranean Diet October 30, 2020 EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab March 4, 2021 New hormone treatment for advanced prostate cancer made available in England June 8, 2021 Load more HOT NEWS New Drugs Raise Old Questions about Treating Cancer during Pregnancy ¿Puede el uso de un microondas causar cáncer? Researchers Discover Way to Help Immunotherapy Better Target Solid Tumors Like... The Grace Project Helps Breast Cancer Survivors Practice Body Acceptance and...
